

- Kavallaris M. Microtubules and resistance to tubulin-binding agents. *Nat Rev Cancer* 2010;10:194–204.
- Nogales E. Structural insights into microtubule function. *Ann Rev Biophys Biomol Struct* 2001;30:397–420.
- Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc* 1971;93:2325–2327.
- Rowinsky E, Donehower R. Antimicrotubule agents. In: DeVita VT, Hellmann S, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*. 5th ed. Philadelphia: Lippincott-Raven;1997.
- Vrignaud P, Sémonod D, Lejeune P, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. *Clin Cancer Res* 2013;19:2973–2983.
- Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. *Clin Breast Cancer* 2000;1:32–40.
- Mamounas E, Leinbersky B, Bryant J, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. *J Clin Oncol* 2005;23:3686–3696.
- Bonomi P, Kim KM, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. *J Clin Oncol* 2000;18:623–631.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. *N Engl J Med* 2005;352:2302–2313.
- Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. *J Clin Oncol* 2005;23:5542–5551.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502–1512.
- Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991–4997.
- Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature* 1979;277:665–667.
- Nogales E. Structural insight into microtubule function. *Annu Rev Biophys Biomol Struct* 2001;30:397–420.
- Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. *Cancer Res* 2011;71:6019–6029.
- Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. *Ther Adv Med Oncol* 2010;2:107–123.
- LaPointe NE, Morfini G, Brady ST, et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy. *Neurotoxicology* 2013;37:231–239.
- Mielgo A, Torres VA, Clair K, et al. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. *Oncogene* 2009;28:3551–3562.
- Komlodi-Pasztor E, Sackett D, Wilkerson J, et al. Mitosis is not a key target of microtubule agents in patient tumors. *Nat Rev Clin Oncol* 2011;8:244–250.
- Sung M, Giannakakou P. BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. *Oncogene* 2014;33(11):1418–1428.
- Strobel T, Kraeft SK, Chen LB, et al. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. *Cancer Res* 1998;58:4776–4781.
- Srivastava RK, Mi QS, Hardwick JM, et al. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. *Proc Natl Acad Sci U S A* 1999;96:3775–3780.
- Dai H, Ding H, Meng XW, et al. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. *Cancer Res* 2013;73(23):6998–7008.
- Oakes SR, Vaillant F, Lim E, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. *Proc Natl Acad Sci* 2012;109:2766–2771.
- Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. *Nat Nanotechnol* 2012;7:383–388.
- Gradishar W, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23:7794–7803.
- Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. *J Clin Oncol* 2012;30:2055–2062.
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691–1703.
- Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). *Clin Cancer Res* 2005;11:4136–4143.
- Yardley DA. nab-Paclitaxel mechanisms of action and delivery. *J Control Release* 2013;170:365–372.
- Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clin Cancer Res* 2006;12:1317–1324.
- Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. *J Clin Oncol* 2005;23:7785–7793.
- Cheng CJ, Saltzman WM. Nanomedicine: downsizing tumour therapeutics. *Nat Nanotechnol* 2012;7:346–347.
- Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. *J Clin Oncol* 2007;25:319–325.
- Kato Y, Nagashima Y, Baba Y, et al. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. *Int J Mol Med* 2005;16:263–268.
- Lau CPY, Poon RTP, Cheung ST, et al. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. *J Pathol* 2006;210:459–468.
- Thomas R, True LD, Basuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. *Clin Cancer Res* 2000;6:1140–1149.
- Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. *Prostaglandins Leukot Essent Fatty Acids* 2005;72:267–272.
- Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. *Biomaterials* 2011;32:6194–6203.
- Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature* 2010;464:1067–1070.
- Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine Plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. *J Clin Oncol* 2011;29:4548–4554.
- Mita A, Denis L, Rowinsky E, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res* 2009;15:723–730.
- Diéras V, Lortholary A, Laurence V, et al. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. *Eur J Cancer* 2013;49:25–34.
- Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res* 2009;15:723–730.
- Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. *Drug Des Devel Ther* 2012;6:371–384.
- Baas P, Szczesna A, Albert I, et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. *J Thorac Oncol* 2008;3:745–750.
- Vigano L, Locatelli A, Grasselli G, et al. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. *Invest New Drugs* 2001;19:179–196.
- Kudlowitz D, Muggia F. Defining risks of taxane neuropathy: insights from randomized clinical trials. *Clin Cancer Res* 2013;19:4570–4577.
- Henningson A, Karlsson MO, Viganò L, et al. Mechanism-based pharmacokinetic model for paclitaxel. *J Clin Oncol* 2001;19:4065–4073.
- Sissung T, Mross K, Steinberg S, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. *Eur J Cancer* 2006;42:2893–2896.
- Marsh S, Paul J, King C, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. *J Clin Oncol* 2007;25:4528–4535.
- Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. *Clin Cancer Res* 2012;18:5099–5109.
- Rugo H, Barry W, Moreno Aspitia A, et al. CALGB 40502/NCCTG N065H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol* 2012;30.
- Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. *Eur J Oncol Nurs* 2009;13:49–59.
- Lee J, Swain S. Peripheral neuropathy induced by microtubule-stabilizing agents. *J Clin Oncol* 2006;24:1633–1642.

56. Alsamrai S, Charpidou AG, Matthey RA, et al. Pneumonitis related to docetaxel: case report and review of the literature. *In Vivo* 2009;23:635–637.
57. Dumitra S, Sideris L, Leclerc Y, et al. Neutropenic enterocolitis and docetaxel neoadjuvant chemotherapy. *Ann Oncol* 2009;20:795–796.
58. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010;376:1147–1154.
59. Zhou XJ, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. *Anticancer Res* 1994;14:1017–1022.
60. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. *Curr Med Chem Anticancer Agents* 2005;5:65–71.
61. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer* 2004;4:253–265.
62. Bender RA, Castle MC, Margileth DA, et al. The pharmacokinetics of [3H]-vincristine in man. *Clin Pharmacol Ther* 1977;22:430–435.
63. Zhou XJ, Martin M, Placidi M, et al. In-vivo and in-vitro pharmacokinetics and metabolism of vinca alkaloids in rat. II. Vinblastine and vincristine. *Eur J Drug Metab Pharmacokin* 1990;15:323–332.
64. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. *J Clin Oncol* 1994;12:1754–1763.
65. Fumoleau P, Guiu S. New vinca alkaloids in clinical development. *Curr Breast Cancer Rep* 2013;5:69–72.
66. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. *Pharmacotherapy* 1998;18:1304–1307.
67. Tobe SW, Siu LL, Jamal SA, et al. Vinblastine and erythromycin: an unrecognized serious drug interaction. *Cancer Chemother Pharmacol* 1995;35:188–190.
68. Peltier A, Russell J. Recent advances in drug-induced neuropathies. *Curr Opin Neurol* 2002;15:633–638.
69. Quasthoff S, Hartung H. Chemotherapy-induced peripheral neuropathy. *J Neurol* 2002;249:9–17.
70. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. *Biochemistry* 1996;35:6806–6814.
71. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. *Ann Oncol* 2003;14:iii26–iii30.
72. Petrylak D, Hussain MHA, Tangen C, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004;351:1513–1520.
73. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502–1512.
74. Lee JJ, Kelly WK. Etoposides: tubulin polymerization as a novel target for prostate cancer therapy. *Nat Clin Pract Oncol* 2009;6:85–92.
75. Kelly WK. Etoposides in prostate cancer. *Urol Oncol* 2011;29:358–365.
76. Kelly K, Zollinger M, Lozach F, et al. Metabolism of patupilone in patients with advanced solid tumor malignancies. *Invest New Drugs* 2013;31:605–615.
77. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunconjugates. *Science* 1993;261:212–215.
78. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. *Cancer J* 2008;14:154–169.
79. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. *Nat Biotechnol* 2003;21:778–784.
80. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. *Cancer Res* 2008;68:9280–9290.
81. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012;367:1783–1791.
82. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. *Clin Cancer Res* 2010;16:888–897.
83. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med* 2010;363:1812–1821.
84. Younes A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. *Hematol Oncol Clin North Am* 2014;28:27–32.
85. Gandhi M, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. *Blood* 2013;122:4380.
86. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. *Neoplasia* 2013;15:1–10.
87. Ujhazy P, Stewart D. DNA Repair. *J Thorac Oncol* 2009;4:S1068–S1070.
88. Green MR, Woolery JE, Mahadevan D. Update on aurora kinase targeted therapeutics in oncology. *Expert Opin Drug Discov* 2011;6:291–307.
89. Jackson JR, Patrick DR, Dar MM, et al. Targeted anti-mitotic therapies: can we improve on tubulin agents? *Nat Rev Cancer* 2007;7:107–117.
90. Tang PA, Siu LL, Chen EX, et al. Phase II study of ipinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. *Invest New Drugs* 2008;26:257–264.
91. Beer TM, Goldman B, Synold TW, et al. Southwest oncology group phase II study of ipinesib in androgen-independent prostate cancer previously treated with taxanes. *Clin Genitourin Cancer* 2008;6:103–109.
92. Lee RT, Beekman KE, Hussain M, et al. A university of chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. *Clin Genitourin Cancer* 2008;6:21–24.
93. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. *Mol Cancer Ther* 2009;8:2086–2095.
94. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2002;2:48–58.
95. Fojo AT, Meneffee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). *Semin Oncol* 2005;32:S3–S8.
96. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. *Clin Cancer Res* 2005;11:298–305.
97. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (review). *Int J Oncol* 2002;21:621–628.
98. Verrills NM, Kavallaris M. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. *Curr Pharm Des* 2005;11:1719–1733.
99. Orr GA, Verdier-Pinard P, McDaid H, et al. Mechanisms of Taxol resistance related to microtubules. *Oncogene* 2003;22:7280–7295.
100. Monzó M, Rosell R, Sánchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. *J Clin Oncol* 1999;17:1786–1793.
101. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. *Mol Cancer Ther* 2005;4:2001–2007.
102. Baquero MT, Hanna JA, Neumeister V, et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. *Cancer* 2012;118:4660–4669.
103. Baquero MT, Lostritto K, Gustavson MD, et al. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. *Breast Cancer Res* 2011;13(5):R85.
104. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. *Clin Cancer Res* 2007;13:7413–7420.
105. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. *Breast Cancer Res Treat* 2008;108:289–296.
106. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. *Ann Oncol* 2011;22:139–144.
107. Reguart N, Cardona AF, Carrasco E, et al. BRCA1: a new genomic marker for non-small-cell lung cancer. *Clin Lung Cancer* 2008;9:331–339.
108. Martin M, Prat A, Rodriguez-Lescure A, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. *Breast Cancer Res Treat* 2013;138:457–466.